AU2002328901A1 - Compositions capable of forming hydrogels in the eye - Google Patents
Compositions capable of forming hydrogels in the eyeInfo
- Publication number
- AU2002328901A1 AU2002328901A1 AU2002328901A AU2002328901A AU2002328901A1 AU 2002328901 A1 AU2002328901 A1 AU 2002328901A1 AU 2002328901 A AU2002328901 A AU 2002328901A AU 2002328901 A AU2002328901 A AU 2002328901A AU 2002328901 A1 AU2002328901 A1 AU 2002328901A1
- Authority
- AU
- Australia
- Prior art keywords
- group
- polymer
- composition according
- photoinitiator
- water soluble
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 title claims description 63
- 239000000017 hydrogel Substances 0.000 title claims description 53
- 229920000642 polymer Polymers 0.000 claims description 70
- 229910001868 water Inorganic materials 0.000 claims description 38
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 36
- 238000004132 cross linking Methods 0.000 claims description 32
- 239000000178 monomer Substances 0.000 claims description 30
- 229920003169 water-soluble polymer Polymers 0.000 claims description 27
- IMROMDMJAWUWLK-UHFFFAOYSA-N Ethenol Chemical compound OC=C IMROMDMJAWUWLK-UHFFFAOYSA-N 0.000 claims description 21
- 229920001577 copolymer Polymers 0.000 claims description 19
- NIXOWILDQLNWCW-UHFFFAOYSA-M acrylate group Chemical group C(C=C)(=O)[O-] NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 claims description 16
- 238000000034 method Methods 0.000 claims description 15
- 230000008961 swelling Effects 0.000 claims description 14
- 238000006243 chemical reaction Methods 0.000 claims description 11
- 230000005540 biological transmission Effects 0.000 claims description 10
- -1 vinyl lactams Chemical class 0.000 claims description 10
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 9
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims description 8
- 230000015572 biosynthetic process Effects 0.000 claims description 8
- 238000011065 in-situ storage Methods 0.000 claims description 8
- MPQXHAGKBWFSNV-UHFFFAOYSA-N oxidophosphanium Chemical group [PH3]=O MPQXHAGKBWFSNV-UHFFFAOYSA-N 0.000 claims description 8
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical group CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 7
- RQLOSVWWQDTFSU-UHFFFAOYSA-N diphenylphosphoryl-(4-ethenyl-2,6-dimethylphenyl)methanone Chemical group CC1=CC(C=C)=CC(C)=C1C(=O)P(=O)(C=1C=CC=CC=1)C1=CC=CC=C1 RQLOSVWWQDTFSU-UHFFFAOYSA-N 0.000 claims description 6
- UYMKPFRHYYNDTL-UHFFFAOYSA-N ethenamine Chemical class NC=C UYMKPFRHYYNDTL-UHFFFAOYSA-N 0.000 claims description 6
- 125000000524 functional group Chemical group 0.000 claims description 6
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 claims description 6
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical group C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims description 5
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical group O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 claims description 5
- 150000003254 radicals Chemical class 0.000 claims description 5
- 239000004593 Epoxy Substances 0.000 claims description 4
- PPBRXRYQALVLMV-UHFFFAOYSA-N Styrene Chemical compound C=CC1=CC=CC=C1 PPBRXRYQALVLMV-UHFFFAOYSA-N 0.000 claims description 4
- HFBMWMNUJJDEQZ-UHFFFAOYSA-N acryloyl chloride Chemical compound ClC(=O)C=C HFBMWMNUJJDEQZ-UHFFFAOYSA-N 0.000 claims description 4
- 230000001476 alcoholic effect Effects 0.000 claims description 4
- FQPSGWSUVKBHSU-UHFFFAOYSA-N methacrylamide Chemical compound CC(=C)C(N)=O FQPSGWSUVKBHSU-UHFFFAOYSA-N 0.000 claims description 4
- 238000007348 radical reaction Methods 0.000 claims description 4
- 125000002348 vinylic group Chemical group 0.000 claims description 4
- 238000010521 absorption reaction Methods 0.000 claims description 3
- SLLLEHZWNVRUNH-UHFFFAOYSA-N (2-methylphenyl)-[phenyl-(2-prop-1-enylphenyl)phosphoryl]methanone Chemical group CC=CC1=C(C=CC=C1)P(C1=CC=CC=C1)(C(C1=CC=CC=C1C)=O)=O SLLLEHZWNVRUNH-UHFFFAOYSA-N 0.000 claims description 2
- LEWNYOKWUAYXPI-UHFFFAOYSA-N 1-ethenylpiperidine Chemical compound C=CN1CCCCC1 LEWNYOKWUAYXPI-UHFFFAOYSA-N 0.000 claims description 2
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 claims description 2
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 claims description 2
- 206010002945 Aphakia Diseases 0.000 claims description 2
- NOWKCMXCCJGMRR-UHFFFAOYSA-N Aziridine Chemical compound C1CN1 NOWKCMXCCJGMRR-UHFFFAOYSA-N 0.000 claims description 2
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 claims description 2
- CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 claims description 2
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 claims description 2
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 claims description 2
- 229940091179 aconitate Drugs 0.000 claims description 2
- 150000003926 acrylamides Chemical class 0.000 claims description 2
- 150000001252 acrylic acid derivatives Chemical class 0.000 claims description 2
- 239000003153 chemical reaction reagent Substances 0.000 claims description 2
- 230000001427 coherent effect Effects 0.000 claims description 2
- BLCTWBJQROOONQ-UHFFFAOYSA-N ethenyl prop-2-enoate Chemical compound C=COC(=O)C=C BLCTWBJQROOONQ-UHFFFAOYSA-N 0.000 claims description 2
- VEWLDLAARDMXSB-UHFFFAOYSA-N ethenyl sulfate;hydron Chemical class OS(=O)(=O)OC=C VEWLDLAARDMXSB-UHFFFAOYSA-N 0.000 claims description 2
- 229940117927 ethylene oxide Drugs 0.000 claims description 2
- WXVQVZBJMWDACQ-UHFFFAOYSA-N isocyanato 2-methylprop-2-enoate Chemical compound CC(=C)C(=O)ON=C=O WXVQVZBJMWDACQ-UHFFFAOYSA-N 0.000 claims description 2
- CQUTXCKGINHWKG-UHFFFAOYSA-N isocyanato prop-2-enoate Chemical compound C=CC(=O)ON=C=O CQUTXCKGINHWKG-UHFFFAOYSA-N 0.000 claims description 2
- LVHBHZANLOWSRM-UHFFFAOYSA-N itaconic acid Chemical compound OC(=O)CC(=C)C(O)=O LVHBHZANLOWSRM-UHFFFAOYSA-N 0.000 claims description 2
- 150000003951 lactams Chemical group 0.000 claims description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 claims description 2
- 239000011976 maleic acid Substances 0.000 claims description 2
- 150000002734 metacrylic acid derivatives Chemical class 0.000 claims description 2
- VHRYZQNGTZXDNX-UHFFFAOYSA-N methacryloyl chloride Chemical compound CC(=C)C(Cl)=O VHRYZQNGTZXDNX-UHFFFAOYSA-N 0.000 claims description 2
- XJRBAMWJDBPFIM-UHFFFAOYSA-N methyl vinyl ether Chemical compound COC=C XJRBAMWJDBPFIM-UHFFFAOYSA-N 0.000 claims description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 2
- 229920002554 vinyl polymer Polymers 0.000 claims description 2
- ZTWTYVWXUKTLCP-UHFFFAOYSA-N vinylphosphonic acid Chemical class OP(O)(=O)C=C ZTWTYVWXUKTLCP-UHFFFAOYSA-N 0.000 claims description 2
- 230000001678 irradiating effect Effects 0.000 claims 2
- 229940088644 n,n-dimethylacrylamide Drugs 0.000 claims 1
- YLGYACDQVQQZSW-UHFFFAOYSA-N n,n-dimethylprop-2-enamide Chemical compound CN(C)C(=O)C=C YLGYACDQVQQZSW-UHFFFAOYSA-N 0.000 claims 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims 1
- 210000000695 crystalline len Anatomy 0.000 description 60
- 239000000243 solution Substances 0.000 description 29
- 230000003993 interaction Effects 0.000 description 17
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 14
- 239000004971 Cross linker Substances 0.000 description 13
- 239000000463 material Substances 0.000 description 13
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
- 239000000499 gel Substances 0.000 description 8
- 239000007924 injection Substances 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 239000007864 aqueous solution Substances 0.000 description 5
- 239000012530 fluid Substances 0.000 description 5
- 239000007943 implant Substances 0.000 description 5
- 238000001723 curing Methods 0.000 description 4
- 229960004132 diethyl ether Drugs 0.000 description 4
- 239000012632 extractable Substances 0.000 description 4
- AUONHKJOIZSQGR-UHFFFAOYSA-N oxophosphane Chemical compound P=O AUONHKJOIZSQGR-UHFFFAOYSA-N 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 230000035882 stress Effects 0.000 description 4
- 238000001356 surgical procedure Methods 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- MHABMANUFPZXEB-UHFFFAOYSA-N O-demethyl-aloesaponarin I Natural products O=C1C2=CC=CC(O)=C2C(=O)C2=C1C=C(O)C(C(O)=O)=C2C MHABMANUFPZXEB-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 239000006185 dispersion Substances 0.000 description 3
- 238000002513 implantation Methods 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 230000003287 optical effect Effects 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- OCKGFTQIICXDQW-ZEQRLZLVSA-N 5-[(1r)-1-hydroxy-2-[4-[(2r)-2-hydroxy-2-(4-methyl-1-oxo-3h-2-benzofuran-5-yl)ethyl]piperazin-1-yl]ethyl]-4-methyl-3h-2-benzofuran-1-one Chemical compound C1=C2C(=O)OCC2=C(C)C([C@@H](O)CN2CCN(CC2)C[C@H](O)C2=CC=C3C(=O)OCC3=C2C)=C1 OCKGFTQIICXDQW-ZEQRLZLVSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 208000002177 Cataract Diseases 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 125000004386 diacrylate group Chemical group 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 239000012299 nitrogen atmosphere Substances 0.000 description 2
- 238000005191 phase separation Methods 0.000 description 2
- 229920003229 poly(methyl methacrylate) Polymers 0.000 description 2
- 239000004926 polymethyl methacrylate Substances 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- CNHDIAIOKMXOLK-UHFFFAOYSA-N toluquinol Chemical compound CC1=CC(O)=CC=C1O CNHDIAIOKMXOLK-UHFFFAOYSA-N 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical group CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- 201000004569 Blindness Diseases 0.000 description 1
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 101710172711 Structural protein Proteins 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 239000004809 Teflon Substances 0.000 description 1
- 229920006362 Teflon® Polymers 0.000 description 1
- 230000004308 accommodation Effects 0.000 description 1
- 230000002350 accommodative effect Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 238000005266 casting Methods 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- AHFCXAVRISCANH-UHFFFAOYSA-N diphenylphosphoryl-(4-isocyanato-3,5-dimethylphenyl)methanone Chemical compound CC1=C(N=C=O)C(C)=CC(C(=O)P(=O)(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1 AHFCXAVRISCANH-UHFFFAOYSA-N 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- FYUWIEKAVLOHSE-UHFFFAOYSA-N ethenyl acetate;1-ethenylpyrrolidin-2-one Chemical compound CC(=O)OC=C.C=CN1CCCC1=O FYUWIEKAVLOHSE-UHFFFAOYSA-N 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229940089982 healon Drugs 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 229920001477 hydrophilic polymer Polymers 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- NWVVVBRKAWDGAB-UHFFFAOYSA-N hydroquinone methyl ether Natural products COC1=CC=C(O)C=C1 NWVVVBRKAWDGAB-UHFFFAOYSA-N 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 229940102223 injectable solution Drugs 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000006140 methanolysis reaction Methods 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 239000011368 organic material Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 238000000016 photochemical curing Methods 0.000 description 1
- 229920002959 polymer blend Polymers 0.000 description 1
- 239000002861 polymer material Substances 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 229920001343 polytetrafluoroethylene Polymers 0.000 description 1
- 239000004810 polytetrafluoroethylene Substances 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 229920013730 reactive polymer Polymers 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 125000006850 spacer group Chemical group 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000012899 standard injection Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000003106 tissue adhesive Substances 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 230000000472 traumatic effect Effects 0.000 description 1
Description
Compositions capable of forming hydrogels in the eye
Field of invention
The present invention refers to aqueous solutions of reactive polymers suitable for the production of hydrogel materials upon irradiation with blue light. The hydrogels are especially useful for production of intraocular lenses, which can be formed in-situ in the capsular bag in an eye having undergone surgical excision of a natural lens.
Background of the invention
The natural lens of the human eye is a precisely formed structure of fibre cells containing about 65 percent water and 35 percent organic material, chiefly structural proteins. The proteins are responsible for the relatively high refractive index of 1.42 of the lens and are structured in such a way that there are negligible local variations in their density, resulting in a transparent lens. Aging or large stresses can change the morphology of the proteins causing a progressive loss of transparency. This is termed cataract formation and is irreversible and can eventually result in blindness. Implantation of an intraocular lens (IOL) following cataract surgery is performed to replace the optical function of the natural lens. In order to remove the natural, cataractous lens, as well as to prepare for the introduction of the IOL, an incision is made into the eye. For many years most IOLs were made of poly(methylmethacrylate), a material with good optical characteristics and compatibility with the tissues of the eye. A disadvantage of PMMA is, however, that it is a very rigid material and the incision must be made large enough, at least 5-6 mm, for implantation of the IOL. With improved devices for less traumatic removal of the natural lens by phacoemulsification, requiring only a rather small, there was a need for lenses with deformable optics. In such small incision surgery an opening of only 3 mm, or less is required. Various silicone, acrylate and hydrogel lenses have been commercialized.
All incisions in the eye are accompanied by trauma, and so, although foldable lenses have been a great improvement, there is still a need for lenses than can be
placed through an even smaller incision. A lens can be implanted through a 1.2 mm opening by injecting the lens material into the capsular bag as a fluid, followed by formation of a solid full size lens in-situ in the eye. An additional advantage of this technique is that, due to the formation of a full sized lens, complications of conventional IOL implantation namely decentration and posterior capsular opacification may be overcome. Full sized lenses show excellent centration and there is evidence that they may prevent posterior opacification (PCO). Hydrogels are a class of materials that are very interesting for an iηjectable lens because they have the added advantage is that their aqueous composition approximates to that of the natural lens.
Hydrogels can be made by crosslinking aqueous polymer or monomer/crosslinker solutions. Since monomers are often toxic, the use of polymers is preferred for applications in the eye. Polymers to which a reactive group is attached, for example, an acrylate group, can be polymerized in the presence of water and form a hydrogel. This is a process of crosslinking polymer or prepolymer solutions have been described before. In US Patent 5,665,840 crosslinkable water- soluble prepolymers based on copolymers of vinylalcohol and vinyllactams are claimed for contact lens application. Several other publications also disclose the production of hydrogels after crosslinking crosslinkable water-soluble (pre)polymers. The crosslinkable water-soluble (pre)polymers are designed to polymerize in a mould yield hydrogel. However, in-situ in the eye, water is present which demands certain specific requirements of the crosslinkable water-soluble prepolymers not described in any of these publications.
It is evident that the coherence of the aqueous solution during injection and prior to crosslinking is very important. This coherence prevents, or limits, the water in the eye from interfering with the solution before crosslinking. Without it, the carefully regulated hydrogel composition, required for generating an IOL of precise refractive index, may be diluted or altered and it is also needed to prevent leakage of polymer from the capsular bag before the polymer is crosslinked. In addition, all hydrogels have an equilibrium water content, which is controlled both by the structure of the hydrogel and its crosslink density. Water- soluble polymers, when crosslinked, have a tendency to swell in water. For this invention it is important that after injecting the aqueous hydrogel solution into the eye, and crosslinking it, the amount of water that it takes up afterwards, the additional
swelling, is limited, that is to say that the solution concentration of water in the injected hydrogel solution is equal to, or very close to, the equilibrium water concentration of the crosslinked hydrogel formed in the eye. Any additional swelling will decrease the refractive index of the lens and in more severe cases will cause collapsing of the capsular bag or even damage the eye.
A few publications and patents describe the design of injectable and crosslinkable water-soluble (pre)polymers and some polymerizations, which form hydrogels in-situ in the eye.
Ravi et al. reported in Polymer Preprints, 1999, 40, 630 on an injectable hydrogel material made by thermally curing poly(ethylenglycol) monoacrylates and diacrylates (PEGMA and PEGDA, respectively). They, were, however, not studied for possible lens refilling material but as potential probes to study the accommodation mechanism. The polymer content and, therefore, the refractive indices of the materials were very low (< 1.36) and the materials showed severe swelling after curing. In the International Patent Application WO 93/02639 an injectable collagen- based intraocular hydrogel lens is described. The concentration collagen was very low which resulted in a low refractive index of the intraocular lens (1.363). It was claimed that high refractive lenses could also be made. To achieve refractive indices closer to that of the natural lens much higher collagen concentrations are needed, than those reported in the patent, and this will increase the problem of swelling, post-injection. In the International Patent Application WO 01/08604 it was claimed that with aqueous solutions of modified linear polymers, accommodative lenses could be prepared in-situ. The water-soluble polymers were modified to low degrees, to obtain lightly crosslinked hydrogels in order to keep the elasticity modulus of the hydrogel lenses low. The moduli of the hydrogels were measured directly after crosslinking the aqueous polymer solution. The hydrogel were, however, after crosslinking not subjected to an aqueous environment. If these materials would be made in the eye in the presence of an excess natural aqueous fluid, densities they may be expected to swell significantly due to their low crosslink density. Such swelling is to the detriment of the refractive indices of the lenses they form.
In the International Patent Application WO 00/47185, a method of producing an injectable hydrogel intraocular lens is described. The hydrogel lens materials are based on macromolecular particles. However, the problems of obatining a suffcient coherence and avoiding additional swelling are not addressed in this disclosure.
It can be concluded that the specific requirements regarding coherence and prevention of additional swelling for injectable hydrogel lenses still needs attention if a clinically acceptable surgical process is to be attained.
Description of the invention
An object of the present invention is to provide an aqueous composition of a water soluble linear polymer that can fill the capsular bag of the eye and upon a crosslinking reaction by means of irridiation with light in the visible range can form a hydrogel intraocular lens implant of a predetermined refractive index. It also an object of the present invention to provide an aqueous composition of a linear water soluble which has suitable coherence to avoid leaking from the capsular bag or avoiding dispersion effects in the capsular bag, while having suitably low retention time before starting the lens forming light induced crosslinking reaction. An another object of the invention is to sufficiently crosslink the lens so that additional swelling is prevented and in this way ensure that the implanted lens permanently retains its predetermined shape and refractive value.
It is a still further object of the invention to provide hydrogel lens with no or minimal extractable polymer material.
In its most general terms the present invention pertains to an aqueous composition of a of water soluble polymers having a sufficiently high coherency that it substantially not is dispersed when being injected into an aqueous environment to undergo a crosslinking reaction into a hydrogel. The water soluble polymers can either be a water-soluble polymer bearing free acrylic, or other vinylic groups capable of facile free radical reaction with a polymeric water-soluble photoinitiator also present in the composition, or a water-soluble polymer bearing both free acrylic, or other vinylic groups capable of facile free radical reaction and photoinitiator groups. Both these polymers will be crosslinked when irradiated with light of wavelengths greater than about 305 nm induces the photoinitiator groups to form free radicals so as to form the hydrogel. Preferably, the aqueous composition shall form a clear hydrogel with a refractive index of between about 1.36 to about 1.45, a transmission of visible light of at least about 35% with no, or substantially no, absorption of water from an aqueous environment during its formation or subsequently thereafter, so it becomes dimensionally stable and substantially free from swelling after the forming crosslinking process. These features will render the aqueous compositions improved
properties to form an intraocular lens, in-situ in the capsular bag of the eye, from which defect natural lens has been surgically excised.
It is an important aspect of the invention that the aqueous composition has a suitable coherence to enable a surgical procedure comprising injection into the capsular bag of the eye and crosslinking to form a lens implant replacing an excised natural crystalline lens. The coherence at zero shear stress of the aqueous composition shall be sufficiently high, so that the injected composition does not leak from the capsular bag and that the composition does not disperse when injected through a standard injection needle into an aqueous environment, such as the capsular bag of the eye. It is therefore preferred that the composition has a zero shear stress viscosity of at least 3.0 Pas, preferably 10.0 Pas, and most preferably greater than 30.0 Pas. At the same time, the coherence of the inventive aqueous composition at zero shear stress must not be too high, since this will lead to an inconveniently long relaxation time of the, injected aqueous composition before it is sufficiently relaxed to assume precisely the interior contours of the capsular bag and is ready to undergo crosslinking into the lens implant. An excessively coherent aqueous composition will compromise the capacity of the capsular bag to act as a forming mould for the lens surface by exerting a backpressure, with the result of an uneven or bumpy surface of the final lens implant. The coherence of an aqueous solution is determined by the interactions between the solvated polymer molecules, and the stronger these interactions the higher the coherence. These interactions derive from some combination of the generally recognized intermolecular forces, van der Waals, polar, H-bonding, and London or dispersion forces, and for polymers an additional form of interaction, chain entanglement, is a significant contributor. Chain entanglements are physical crosslinks, which occur in polymer solutions, where the polymer has a molecular weight above a context-determined threshold. The degree of chain entanglement is also concentration dependent. These various interactions combine in any given solution to determine that solution's viscosity, and so a solution's viscosity is a useful indicator of its coherence threshold. In order to determine if the presently invented compositions exhibit a sufficient coherency, rheological tests similar to those provided in Carbohydrate Polymers, 2000, 47, 109-119 (GS Harding et al) can be followed. According to these to tests cohesive compositions of hyaluronic acid, such as Healon® 5, have a
distinguishable behavior when flowing in PTFE tube that are desirable for the presently invented compositions.
In the present invention the interactions between the polymer chain is determined by the chemical nature of the modified polymer the concentration and the molecular weight. Generally, a polymer modified with a hydrophobic crosslinker, will have greater coherence for a given molecular weight and concentration than a polymer modified with a hydrophilic crosslinker, where a higher molecular weight or concentration is needed for the same coherence. It is a part of the present invention to select the polymer, its molecular weight, the functional groups for crosslinking and polymer concentration in such a way that the refractive index of the aqueous solution and the coherence are in a suitable range for an injectable solution that shall form a lens implant with a controlled and predetermined refractive value.
It is a prerequisite for the present invention that the aqueous composition shall have suitable refractive to be able to provide a lens with a refractive index similar to that of the natural crystalline lens, i.e. the composition shall have a refractive index in the range of about 1,36 to 1.45. For a given hydrophilic polymer, the refractive index of a hydrogel lens is dependent upon both the mole fraction of the polymer, and the mole fraction of water in the hydrogel and the refractive index of each. Experience has shown that, for example, when polyvinyl alcohol with a refractive index of 1.51 is used to form a hydrogel, a polymer concentration of 14 to 54 wt% is needed to obtain refractive indices of 1.36 to 1.45. For the linear, water soluble, polymers employed in the present invention, the aqueous concentration required to obtain any desired refractive index will exceed the critical concentration of about 5%. Above this concentration polymer coils start to overlap and the polymer solutions to attract water, to reduce the concentration. If the equilibrium concentration is not attained during injection swelling of the formed crosslinked gel, the lens, will result as it reverts to its equilibrium water content. According to the present invention, the tendency of swelling of the finally crosslinked lens is entirely or substantially eliminated by introducing a sufficiently high crosslink density, as is dependent by the amount of the introduced functional groups for crosslinking on the linear water soluble polymers and above exemplified with acrylate groups. The interaction parameter of the polymer and the crosslinker with water will determine the optimal crosslink density. When the polymer as well as the crosslinker have a relatively high interaction parameter with water, more crosslinks are needed to prevent additional swelling, compared to a
polymer and crosslinker with a lower interaction parameter. This also counts for the interaction parameter of the polymer and crosslinker separately. If the same polymer is used, and a crosslinker with a high interaction parameter is used, the needed crosslink density is higher than in case of a crosslinker with a lower interaction parameter. With the same crosslinker, a polymer with a high interaction parameter needs more crosslinks than a polymer with a low interaction parameter. The interaction parameters χ of the polymer and crosslinker will also determine the transparency of the hydrogel. When the interaction parameter of the polymer and crosslinkers are too different, this means that the two components are not miscible which will lead to phase separation and opacification of the hydrogel. For a good transmission the interaction parameters of the crosslinker and polymer should be in the same range. In a preferred embodiment hydrophilic water soluble polymers are copolymers of vinyl alcohol and have at least one monomer unit having a lactam group, such as vinyl pyrrolidone. Further, the copolymers have at least one monomer unit capable of acting as a functional group in the crosslinking reaction, such as an acrylate group or a derivative thereof. Advantageously these monomer units are randomly distributed on the polymer chains and present in an amount yielding between about 15 and 20 mol% of acrylate groups to obtain a sufficiently high crosslinking density. A complementing advantage of a highly crosslinked hydrogel according to the present invention, is that all the polymer chains are incorporated into the gel and so the system has no, or a minimum amount of extractable agents.
In one embodiment, the present invention relates to a mixture of two water- soluble polymers of which one is a polymer having functional groups for crosslinking attached and one is a polymer having photoinitiator groups attached. The copolymers have a general formula (A)m(B)n(C)p(D)q and (A)m(B)n(D)q(E)rin which A can one of the following monomer: vinyl amides, vinyl lactams, acrylamide, methacrylamide, N- substitued acrylamides, N-substitued methacrylamides, vinylamine, ethyleneoxide, vinylsulfuric acids, vinylphosphonic acids, maleic acid, vinylpiperidine, vinylacrylate, methylvinylether, ethylene imine, methacrylic acid, acrylic acid, and vinylammonium salts. B is vinylalcohol or similar alcoholic group, C is a crosslinkable group attached to vinylalcohol or another alcoholic group, by its reaction with a suitable reagent such as acrylic acid chloride, methacrylic acid chloride, isocyanato acrylate, isocyanato
methacrylate, epoxy acrylates, epoxy methacrylates, or itaconate or aconitate acid anhydride. D is optionally a monomer to modify the refractive index of the polymer, such as methylmethacrylate, styrene, or methyl- or benzyl-N-acetamidoacrylate, and E is a photoinitiator moiety carrying a photoinitiating group which is described per se in the International Patent Application WO 00/55214 which hereby is incorporated as a reference.
An alternative to this polymer mixture is a water-soluble copolymer to which both the functional group for crosslinking and the photoinitiator group are attached to the and has the following general formula (A)m(B)n(C)p(D)q(E)r where A, B, C, D, E are equally as described above.
According to a preferred embodiment, the water soluble polymer has the general formula:
(A)m(B)n(C)p(D)q in which A, B, C and D are each are vinyl groups (-CH2-CH-) to which a pyrrolidone group (A), a hydroxyl or acetate group (B), an acrylate group (C), and a photoinitiator group (D), respectively, is attached; and where the respective mole fractions of the different monomer units is: m=0.1-0.5; n=0.1 to 0.5; p=0.1-0.2; and q=0.0-0.1. The photoinitaitor groups and the acrylate groups are preferably randomly distributed on the polymer chains. Most advantageously, all groups A, B, C and D are randomly distributed along the chains in order to avoid zones with different hydrophilic characteristics which at worst may lead to phase separation and a compromised optical quality.
The photoinitiator groups are preferably selected so as to be able to bring about a crosslinking reaction induced by irradiation with blue light at a wavelength of about 400 to 500 nm. To accomplish this performance, the photoinitiator groups suitably comprise a phosphine oxide moiety. Typically suitable monomers (D) are 2,6-dimethylvinylbenzoyldiphenylphosphine oxide, preferably 2,6-dimethyl-4- vinylbenzoyldiphenylphosphine oxide that typically can be present in an mole fraction of amount in the range of about 0.05 to 0.25. In a specific example of the aqueous composition the water soluble polymer can follow the formula (A)ra(B)n(C)p(D)q , wherein A, B, C and D are each are vinyl groups (-CH2-CH-) to which a pyrrolidone group (A), a hydroxyl or acetate group (B), an acrylate group (C), respectively is attached and ,where the respective mole fractions of the different monomer units are: m=0.1-0.5; n=0.1-0.5; p=0.1-0.2; and
q=0. The photoinitiator is present as a separate water soluble polymer entity, which is a copolymer of 2,6-dimethyl-4-vinylbenzoyldiphenylphosphine oxide andN,N- dimethylacrylamide with 2,6-dimethyl-4-vinylbenzoyldiphenylphosphine oxide present in the water soluble photoinitiator in mole fractions in the range of 0.05 to 0.25. Alternatively, the photoinitiator is present as a separate water soluble polymer having the formula (A)m(B)n(D)q, wherein A, B and D are each are vinyl groups (- CH2-CH-) to which a pyrrolidone group (A), a hydroxyl or acetate group (B), and a photoinitiator group (D), respectively, is attached; and where the respective mole fractions of the different monomer units is: m=0.1 to 0.5; n=0.1 to 0.5 and q=0.05- 0.25. In the photoinitaitor group (D) the phosphine oxide can be linked to the vinyl groups through a urethane band as outlined in detail in the above mentioned WO 00/55214. In this specific example of the invention the water soluble polymer to be reacted with the polymeric photoinitiator suitably is a copolymer of vinyl pyrrolidone and vinyl alcohol wherein a fraction of the hydroxyl groups modified with a functional acryl group for crosslinking. Typically about 15 to 20 mol% of the hydroxyls are modified in order to obtain the suitable crosslinking density as earlier discussed.
The aqueous compositions so far disclosed typically will find use in methods of forming a rigid and dimensionally stable hydrogel intraocular lens in situ in the eye by. The compositions will be injected with a conventional syringe into the capsular bag of the aphakic eye. Due to the suitable coherence and viscosity of the composition this can be performed without complications in the form high injection pressure, air bubble formation or material dispersion which otherwise may jeopardize patient safety or lens quality. Subsequent to injection and relaxation of the material the eye is irradiated with a sufficient amount of light exceeding about 305 nm, preferably with blue light to form the hydrogel lens
The present invention also relates a method of forming a dimensionally stable clear hydrogel that includes at first the provision of a vinyl alcohol monomer containing polymer having a refractive index of at least 1.41. A first part of the polymer is chemically modified so a sufficient amount of a first part of said vinyl alcohol monomers obtains functional acrylic groups for crosslinking. A second part of said vinyl alcohol containing polymer is chemically modified by attaching a blue light activated photoactive group comprising a phosphine oxide moiety, for example by means of an urethane bond, so as to obtain a polymeric water soluble photoinitaitor.
The first and second part is mixed into an injectable aqueous composition with a sufficient polymer concentration to obtain a refractive index of about 1.36 to 1.45. Finally, the composition is injected into the eye or into another body site and irradiated with light of a wavelength exceeding about 400 nm, so as to form a hydrogel by means of crosslinking.
Besides preparation of intraocular lenses the inventive aqueous hydrogel forming compositions will find use in numerous other medical applications including tissue engineering, tissue adhesive processes. The hydrogels may also act as slow release or depot formulations for a wide variety of pharmaceuticals as for example illustrated by, but not limited to agents that inhibit epithelial cell growth on an implanted intraocular lens.
The following detailed description aims to illustrate examples of hydrogels according to present invention and should not be regarded as limiting for the scope of the invention or its applicability.
Detailed and exemplifying part of the description
Fig. 1 shows a surgical procedure for the formation of an IOL in a pig's eye with a hydrogel forming composition according to the invention
Examples: 1.Modification of water-soluble polymers with reactive groups
Example 1 A: Methanolysis of N-vinylpyrrolidone/vinylacetate (60/40 copolymer
The acetate groups of the copolymer were hydrolyzed by dissolving the copolymer (40.0g, 0.16 mol acetate groups, Mw 60000, Mn 20000) in methanol (200ml). A solution of NaOH (6.4 g, 0.16 mol) in water (8ml) was added to the solution. The solution was heated to 40°C for 24 h and afterwards neutralized with 2M HCl.The solution was poured into dialyzing tubes (Spectrapor 2000 MWCO 1000) and dialyzed against frequently refreshed reversed osmosis (RO) water for two days. The polymer solution was concentrated in a rotary evaporator, diluted with methanol (100ml) and precipitated in diethylether (11). The polymer, copoly(N- vinylpyrrolidone/vinylalcohol) copoly(NNP/VA), was dried in an oven, pulverized
and further dried in a vacuum oven connected to an oil pump above Sicapent for at least one week. The oven was ventilated with nitrogen to prevent water absorption. The degree of hydrolysis was checked with IR (Perkin Elmer Spectrum 1).
Example IB: Acrylation of NNP/VA copolymer
Dried copoly(ΝNP/VAC) 60/40 (2.0 g, 9.5 mmol OH groups, from example 1 A) was dissolved in 45 ml DMAC at 40°C under nitrogen atmosphere. 5 ml solution of 6.9 ml acryloylchloride in 43.1 ml DMAC (8.5 mmol ) was added slowly to the polymer solution at room temperature. A small amount of methylhydroquinone was added and the solution was heated to 40°C overnight. The reaction mixture was protected from light by aluminum foil. The solution was neutralized with a small amount of sodium bicarbonate. The polymer was precipitated in diethylether and redissolved in 25 ml methanol to precipitate the salts. The solutions was decanted and precipitated in a 10-fold excess of diethylether. The polymer was dried in a vacuum stove. The degree of modification was determined by 1H nmr (Varian Unity 300).
Example 1C: Introduction of phosphineoxide groups
This reaction was performed in subdued light under an inert nitrogen atmosphere. To an oven dried three-neck flask 18.5 mol% acrylate modified copoly(ΝNP/VA) (2g, xmmoi), as is described in example IB was dissolved in 25 ml DMSO. To this solution, 4-isocyanato-3,5-dimethylbenzoyldiphenylphosphineoxide (0.2g, yrnmol) in 10 ml DMAC was added at 40°C. After standing overnight the reaction mixture was poured into an excess of diethylether.The light yellow polymer precipitated was collected by filtration, dissolved in methanol (30ml) and reprecipitated in ether.. The polymer was dried in a vacuum oven at room temperature. A 1H-ΝMR scan in DMSO-d6 of the phosphineoxide modified acrylated copoly(NVP/VA) revealed that the PO substitution was 1.1 mol%.
Example 2: The photopolvmerization of a series of polyethyleneglycol diacrylates. PEGDA. (MWs in the range 250 to 40000
Example 2A
A polymeric acylphosphineoxide photocrosslinker (0.050 g), for which the synthesis is described in WO 00/55214, and PEGDA (0.450 g) of which the molecular weight of the PEG part was 258, were dissolved in 0.5 g saline under dark circumstances. The solution was sucked into a syringe with an 18G needle. The solution was poured between two microscopic glass plates separated by teflon spacer (diameter 1 cm, thickness of 4 mm). The mould was illuminated with blue light (500mW/cm2) for 2 minutes. The appearance, equilibrium water content, mass loss and transmission are presented in table 1.
Examples 2B to 20
The appearance, equilibrium water content, extractables and transmission of other gels prepared, in like manner to example 2 A, from PEGDAs in a range of PEG MWs from 258 to 4000D are also collected in table 1.
Example 3: Photopolymerization of acrylate modified copolvfNNP/VA .
Example 3A
0.025 g PPI and 0.475 g, 2.0 mol% acrylate modified copoly(NNP/VA), were dissolved in 0.5 g saline in the dark. The solution was sucked into a syringe with an 18G needle. The polymer solution in the syringe was degassed by centrifugation at 3000 rpm. The solution was injected into a casting cell to produce a sample of a photocast gel as described in example 2A. The appearance, equilibrium water content, mass loss and transmission of this gel (3 A) are presented in table 2.
Examples 3B to 3S
The appearance, equilibrium water content, mass loss and transmission of Examples 3B to 3S, which are of gels were prepared in like manner to Example 3 A, are also collected in Table 2.
Table 1. Photocuring of polvethyleneglycoldiacrylates (PEGDA) with a polymeric phosphine oxide photoinitiator (PPI)
Example PPI PEGDA+PPI PEGDA Curing Time Appearance EWC" Extractables Transmission
(wt% of PEGDA) ( t% in H2O) (MW D) (s t0.5Wcm2) Of Gel (wt%) ( t%) (%@480nm)
2A 10.0 50 258 120 White 70 ±1 _ b -
2B 10.0 50 575 120 Opaque 55 ±1 - -
2C 10.0 50 700 120 Slightly opaque 56 ±1 - -
2D 10.0 50 4000 120 Clear 89 ±1 - -
2E 1.0 50 700 120 Clear 54±1 - -
2F 2.5 50 700 120 Clear 54 ±1 - -
2G 5.0 50 700 120 Clear 54±1 - -
2H 5.0 50 700 10 s Clear 54±1 1.7 + 0.5 89 ±1
21 5.0 50 700 30 s Clear 54 ±1 1.4 ±0.5 91 ±1
2J 5.0 50 700 120 s Clear 54±1 0.9 ±0.5 84±1
2K 5.0 50 700 150 s Clear 54 ±1 1.4 ±0.5 87 ±1
2L 0.5 50 700 30s(at2.0Wcm2) Clear 57 ±1 1.5 ±0.5 76 ±1
2M 1.0 50 700 30s(at2.0Wcm2) Clear 54 ±1 0.7 ±0.5 90 + 1
2N 2.5 50 700 30s(at2.0Wcm2) Clear 54±1 1.2 ±0.5 90 ±1 O 5.0 50 700 30s(at2.0Wcm2) Clear 54 ±1 1.0 ±0.5 91 ±1
Equilibrium water content, not measured
Table 2. Cast gels prepared by photopolymerisation of acrylated copolvNNP/VA & PPI
PPI PPI+ΝVP/VA Acrylate Curing time Appearance MassLoss
Example # EWC Transmission
( t% of ΝVP/VA) (wt% in H20) (mole% of ΝVP/VA) (min@0.5W) (wt%) (wt%) (%@480nm)
3A 5.0 50 2.0 ±0.5 2 White 81 ±1 _ b -
3B 5.0 50 4.5 +0.5 2 Opaque 78+1 - -
3C 5.0 50 8.0 ±0.5 2 Opaque 56±1 - -
3D 5.0 50 12.0 + 0.5 2 Slightly opaque 52 ±1 - -
3E 5.0 50 15.0 + 0.5 2 Translucent 52 ±1 - -
3F 5.0 50 16.2 ±0.5 2 Yellow clear 52 ±1 0.0 25 + 1
3G 5.0 50 17.7 + 0.5 2 Yellow clear 52+1 0.0 28 ±1
3H 5.0 50 19.9 + 0.5 2 Translucent 52 ±1 - -
31 5.0 50 18.5 + 0.5 0.5 Fluid - - -
3J 5.0 50 18.5 + 0.5 1 Fluid - - -
3K 5.0 50 18.5 + 0.5 1.5 White pieces - - -
3L 5.0 50 18.5 + 0.5 2 Yellow clear 52 + 1 0.0 + 0.5 33 + 1
3M 5.0 50 18.5 ±0.5 3 Yellow clear 52±1 0.0 ±0.5 35 + 1
3Ν 5.0 50 18.5 ±0.5 4 Yellow clear 51±_1 0.0 ±0.5 37 ±1
3O 5.0 50 18.5 + 0.5 2(@2Wcm2) Yellow clear 51 ±1 0.0 ±0.5 40 ±1
3P 1.0 50 15.0 ±0.5 2 Fluid - - -
3Q 2.5 50 15.0 + 0.5 2 Opaque - - -
3R 5.0 50 15.0 ±0.5 2 Yellow clear - - -
3S 10 50 15.0 + 0.5 2 Opaque - - -
a Equilibrium water content, b not measured
Pas. The shapes of the lenses formed are presented in Table 3.
Table 3 Niscosities at zero shear rate of solutions used to form lenses in pigs' eves and the resulting lens shapes.
Example # η (Pas) Lens shapea
5A 0.15 -
5B 0.80 -
5C 3.0 ±
5D 12 +
5E 30 +
5F 80 +
5G 200 +
1 Incompletely formed "■ Partially formed "+- Well formed " «± I 5?
Claims (30)
1. An aqueous composition of water soluble polymers having a sufficiently high coherency that it substantially not is dispersed when being injected into an aqueous environment to undergo a crosslinking reaction into a hydrogel, wherein the water soluble polymers either can be (i) a water-soluble polymer bearing free acrylic, or other vinylic groups capable of facile free radical reaction with a polymeric water-soluble photoinitiator also present in the composition, or (ii) a water-soluble polymer bearing both free acrylic, or other vinylic groups capable of facile free radical reaction and photoinitiator, wherein both polymers are capable of being crosslinked when irradiated with light of wavelengths greater than about 305 nm to form the hydrogel.
2. An aqueous composition according to claim 1 characterized in that it has a solution viscosity such that it is coherent when injected in an aqueous environment, and preferably that said composition has a zero shear stress viscosity of at least 3.0 Pas, preferably 10.0 Pas, and most preferably greater than 30.0 Pas.
3. An aqueous composition according to claims 1 and 2 , wherein said water soluble polymer is a linear polymer capable of providing the resulting hydrogel with
(i) a refractive index of between about 1.36 and about 1.45;
(ii) a transmission of visible light of at least about 35%;
(iii) no or substantially no absorption of water from an aqueous environment during its formation or subsequently, and so is dimensionally stable and substantially free from swelling.
4. An aqueous compositions according to claim 1, wherein said hydrophilic water soluble polymers are copolymers of vinyl alcohol.
5. A composition according to claim 1, wherein said copolymers have at least one monomer unit having a lactam group.
6. A composition according to claim 5, wherein said monomer unit is vinyl pyrrolidone
7. A composition according to any of claims 4 to 6, wherein said copolymers further have at least one monomer unit capable of acting as a functional group in the crosslinking reaction.
8. A compositions according to claim 7, wherein said monomer unit comprises an acrylate group or a derivative thereof.
9. A composition according to claim 8, wherein said monomer unit is randomly distributed on the polymer chains.
10. A composition according to claim 8, wherein said polymer comprises between about 15 and 20 mol% of said acrylate groups.
11. A composition according to claim 1 wherein the water soluble polymers have the general formulas (A)m(B)n(C)p(D)q or (A)m(B)n(D)q(E)r in which A can one of the following monomer: vinyl amides, vinyl lactams, acrylamide, methacrylamide, N- substitued acrylamides, N-substitued methacrylamides, vinylamine, ethyleneoxide, vinylsulfuric acids, vinylphosphonic acids, maleic acid, vinylpiperidine, vinylacrylate, methylvinylether, ethylene imine, methacrylic acid, acrylic acid, and vinylammonium salts. B is vinylalcohol or similar alcoholic group, C is a crosslinkable group attached to vinylalcohol or another alcoholic group, by its reaction with a suitable reagent such as acrylic acid chloride, methacrylic acid chloride, isocyanato acrylate, isocyanato methacrylate, epoxy acrylates, epoxy methacrylates, or itaconate or aconitate acid anhydride. D is optionally a monomer to modify the refractive index of the polymer, such as methylmethacrylate, styrene, or methyl- or benzyl-N-acetamidoacrylate, and E is a photoinitiator moiety carrying a photoinitiating group.
12. A composition according to any of claims 4 to 11, wherein said water soluble polymers have the general formula:
(A)m(B)n(C)p(D)q in which A, B, C and D are each are vinyl groups (-CH2-CH-) to which a pyrrolidone group (A), a hydroxyl or acetate group (B), an acrylate group (C), and a photoinitiator group (D), respectively, is attached; and where the respective mole fractions of the different monomer units is: m=0.1-0.5; n=0.1 to 0.5; p=0.1 to 0.2; and q=0.0 to 0.1.
13. A composition according to any of claim 12, wherein said photoinitiator group is randomly distributed on the polymer chains.
14. A composition according to any of claims 1 to 13 characterized in that the crosslinking reaction is performed with blue light at a wavelength of about 400 to 500 nm.
15. A composition according to claim 13, wherein the photoinitiator group comprises a phosphine oxide moiety.
16. Compositions according to claim 15, wherein the monomer unit bearing the phosphine oxide moiety is 2,6-dimethylvinylbenzoyldiphenylphosphine oxide, where the preferred monomer unit bearing the phosphine oxide moiety is 2,6-dimethyl-4- vinylbenzoyldiphenylphosphine oxide.
17. A composition according to claim 1 comprising a water soluble polymer according to any of claims 4 to 11 free of monomers bearing photoinitiator groups and a water soluble polymeric photoinitiator bearing photoinitiator groups that is a copolymer of 2,6- dimethyl-4-vinylbenzoyldiphenylphosphine oxide and N,N-dimethylacrylamide.
18. A composition according to claim 17, wherein the 2,6-dimethyl-4- vinylbenzoyldiphenylphosphine oxide is present in the water soluble photoinitiator in mole fractions in the range of 0.05 to 0.25.
19. A composition according to claim 1 comprising a water soluble polymer according to any of claims 4 to 12 free of monomers bearing photoinitiator groups and a water soluble polymeric photoinitiator having the formula:
(A)m(B)n(D)q in which A, B and D are each are vinyl groups (-CH2-CH-) to which a pyrrolidone group (A), a hydroxyl or acetate group (B), and a photoinitiator group (D), respectively, is attached; and where the respective mole fractions of the different monomer units is: m=0.1 to 0.5; n=0.1 to 0.5 and q=0.05 to 0.25.
20. A composition according to claim 19, wherein the photoinitiator group comprises a phosphine oxide moiety linked to the main polymer chain by a urethane bond.
21. A composition according to claim 19, wherein the water soluble polymer free of monomers bearing photoinitiator groups is a copolymer of vinylpyrrolidone and vinyl alcohol having a fraction of its hydroxyl group modified with a functional acryl group for crosslinking.
22. A composition according to claim 21, wherein the water soluble polymeric photoinitiator is a copolymer of vinylpyrrolidone and vinyl alcohol having a phosphine oxide moieties attached thereto by means of a urethane bond.
23. A composition according to any of claims wherein the concentration of polymer is about 14 to 54 wt %.
24. A method of forming a rigid and dimensionally stable hydrogel intraocular lens in situ in the eye, characterized by injecting a composition according to any of claims 1-23 into the capsular bag of the aphakic eye, irradiating said eye by a sufficient amount of light exceeding about 305 nm and thereby forming the hydrogel lens.
25. An intraocular lens formed from any of the compositions according claims 1-23.
26. A method of forming a dimensionally stable clear hydrogel comprising the steps of
(i) providing a vinyl alcohol monomer containing polymer having a refractive index of at least 1.41;
(ii) chemically modifying a sufficient amount of a first part of said vinyl alcohol monomers in said vinyl alcohol containing polymer so as to obtain a hydrophilic water soluble polymer having functional acrylic groups for crosslinking;
(iii ) chemically modifying a second part of said vinyl alcohol containing polymer by attaching a blue light activated photoactive group comprising a phosphine oxide moiety by means of an urethane bond so as to obtain a polymeric water soluble photoinitaitor;
(iv) providing an injectable aqueous composition of said first and second parts having a refractive index of about 1.36 to 1.45; and
(v) irradiating said aqueous composition with light of a wavelength exceeding about 400 nm, so as to form a hydrogel by means of crosslinking.
27. A method according to claim 26 characterized by modifying the vinyl alcohol monomers of step (ii) with an acrylic acid chloride.
28. A method according to claim 26 or 27 characterized by introducing about 15 to 20 mol% of acrylate groups.
29. A method according to claim 26, wherein the vinyl alcohol containing polymer is a copolymer of polyvinyl pyrrolidone and vinyl alcohol.
29. A method according to claim 25 wherein the aqueous composition provided in step (iv) has a zero shear stress viscosity of at least 3.0 Pas.
30. A hydrogel formed from any of the methods according to claims 23 to 29 having a water equilibrium content less than about 50% wt, a transmission of light at 480 nm in the range of 35 to 45% and being substantially free from additional swelling after crosslinking.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE0102543-6 | 2001-07-16 | ||
| SE0102543A SE0102543D0 (en) | 2001-07-16 | 2001-07-16 | Compositions capable of forming hydrogels in the eye |
| PCT/EP2002/007878 WO2003009014A1 (en) | 2001-07-16 | 2002-07-15 | Compositions capable of forming hydrogels in the eye |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2002328901A1 true AU2002328901A1 (en) | 2003-05-22 |
| AU2002328901B2 AU2002328901B2 (en) | 2007-11-15 |
Family
ID=20284872
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2002328901A Expired AU2002328901B2 (en) | 2001-07-16 | 2002-07-15 | Compositions capable of forming hydrogels in the eye |
Country Status (6)
| Country | Link |
|---|---|
| EP (1) | EP1410074B1 (en) |
| JP (1) | JP2004535511A (en) |
| AU (1) | AU2002328901B2 (en) |
| CA (1) | CA2452833C (en) |
| SE (1) | SE0102543D0 (en) |
| WO (1) | WO2003009014A1 (en) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8439974B2 (en) | 2006-05-03 | 2013-05-14 | Vision Crc Limited | Adjusted index of refraction of ocular replacement material |
| WO2007149804A2 (en) * | 2006-06-22 | 2007-12-27 | Ethicon, Inc. | Lactam polymer derivatives |
| US20080001320A1 (en) * | 2006-06-28 | 2008-01-03 | Knox Wayne H | Optical Material and Method for Modifying the Refractive Index |
| JP2010500064A (en) * | 2006-08-08 | 2010-01-07 | フンダシオン イナスメット | Implantable optical system, procedure for its development and application |
| US20110124025A1 (en) * | 2009-11-20 | 2011-05-26 | College Of Nanoscale Science And Engineering | Cell Collecting Devices and Methods for Collecting Cells |
| US9372282B1 (en) | 2011-08-31 | 2016-06-21 | Novartis Ag | Styrenic ophthalmic and otorhinolaryngological materials and devices formed therewith |
| US9486311B2 (en) | 2013-02-14 | 2016-11-08 | Shifamed Holdings, Llc | Hydrophilic AIOL with bonding |
| JP6016768B2 (en) | 2013-02-21 | 2016-10-26 | 富士フイルム株式会社 | Ink composition, ink jet recording method, and polymer initiator |
| US10195018B2 (en) | 2013-03-21 | 2019-02-05 | Shifamed Holdings, Llc | Accommodating intraocular lens |
| JP6838964B2 (en) | 2013-03-21 | 2021-03-03 | シファメド・ホールディングス・エルエルシー | Adjustable intraocular lens |
| JP6267832B2 (en) | 2014-08-26 | 2018-01-24 | シファメド・ホールディングス・エルエルシー | Adjustable intraocular lens |
| EP3376999B1 (en) | 2015-11-18 | 2021-08-04 | Shifamed Holdings, LLC | Multi-piece accommodating intraocular lens |
| US11141263B2 (en) | 2015-11-18 | 2021-10-12 | Shifamed Holdings, Llc | Multi-piece accommodating intraocular lens |
| KR20180089474A (en) * | 2015-12-02 | 2018-08-08 | 오타고 이노베이션 리미티드 | Photo-activated preparation of hydrogel |
| CN120000379A (en) | 2016-12-23 | 2025-05-16 | 施菲姆德控股有限责任公司 | Multi-piece accommodative intraocular lens and methods of making and using the same |
| US10350056B2 (en) | 2016-12-23 | 2019-07-16 | Shifamed Holdings, Llc | Multi-piece accommodating intraocular lenses and methods for making and using same |
| CN110996848B (en) | 2017-05-30 | 2023-08-04 | 施菲姆德控股有限责任公司 | Surface treatment of accommodating intraocular lenses and related methods and apparatus |
| US11266496B2 (en) | 2017-06-07 | 2022-03-08 | Shifamed Holdings, Llc | Adjustable optical power intraocular lenses |
| EP3996629A4 (en) | 2019-07-11 | 2023-08-09 | Shifamed Holdings, LLC | Accommodating intraocular lenses and associated methods |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4919151A (en) | 1987-07-06 | 1990-04-24 | California Institute Of Technology | Synthetic polymer for endocapsular lens replacement |
| US5147394A (en) * | 1987-10-09 | 1992-09-15 | Siepser Steven B | High refractive index polymeric compositions suitable for use as expansile hydrogel intraocular lenses |
| US4978713A (en) * | 1987-12-16 | 1990-12-18 | Ciba-Geigy Corporation | Polyvinyl alcohol derivatives containing pendant vinylic monomer reaction product units bound through ether groups and hydrogel contact lenses made therefrom |
| WO1993002639A1 (en) | 1991-08-06 | 1993-02-18 | Autogenesis Technologies, Inc. | Injectable collagen-based compositions for making intraocular lens |
| US5665840A (en) | 1994-11-18 | 1997-09-09 | Novartis Corporation | Polymeric networks from water-soluble prepolymers |
| SE9800853D0 (en) | 1998-03-16 | 1998-03-16 | Pharmacia & Upjohn Bv | Intraocular lens |
| US6007833A (en) * | 1998-03-19 | 1999-12-28 | Surmodics, Inc. | Crosslinkable macromers bearing initiator groups |
| NZ510807A (en) * | 1998-10-13 | 2003-10-31 | Pharmacia Groningen Bv | Injectable intraocular lens |
| SE9900935D0 (en) | 1999-03-16 | 1999-03-16 | Pharmacia & Upjohn Bv | Macromolecular compounds |
| AUPQ197799A0 (en) | 1999-08-02 | 1999-08-26 | Commonwealth Scientific And Industrial Research Organisation | Hydrophilic biomedical compositions |
| SE0001934D0 (en) * | 2000-05-24 | 2000-05-24 | Pharmacia & Upjohn Bv | Method of implantation in intraocular lens |
-
2001
- 2001-07-16 SE SE0102543A patent/SE0102543D0/en unknown
-
2002
- 2002-07-15 AU AU2002328901A patent/AU2002328901B2/en not_active Expired
- 2002-07-15 JP JP2003514299A patent/JP2004535511A/en active Pending
- 2002-07-15 WO PCT/EP2002/007878 patent/WO2003009014A1/en not_active Ceased
- 2002-07-15 EP EP02764698A patent/EP1410074B1/en not_active Expired - Lifetime
- 2002-07-15 CA CA2452833A patent/CA2452833C/en not_active Expired - Lifetime
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6747090B2 (en) | Compositions capable of forming hydrogels in the eye | |
| AU2002328901B2 (en) | Compositions capable of forming hydrogels in the eye | |
| AU2002328901A1 (en) | Compositions capable of forming hydrogels in the eye | |
| AU559551B2 (en) | Hydrogels of modified solubilized collagen | |
| EP0070897B1 (en) | Contact lenses made from modified synthetic hydrogels | |
| AU755254B2 (en) | Methods of producing intraocular lenses and materials suitable for their production | |
| DE102013221204B4 (en) | Silicone-free hydrogel, process for its preparation, molded part thereof, and uses | |
| EP1077952A1 (en) | Polymerizable hydrophilic ultraviolet light absorbing monomers | |
| JP2002528043A (en) | Optically transparent ultraviolet absorbing biocompatible polymer material based on collagen and method for producing the same | |
| JP2002539297A (en) | Hydrophilic polymer compound | |
| EP0034174B1 (en) | Hydrogel implant article and method | |
| EP1210034A1 (en) | Hydrophilic biomedical compositions | |
| CN115433327B (en) | Artificial crystal material and preparation method and application thereof | |
| JP3561740B2 (en) | Biocompatible, optically transparent collagen-based polymer material and method for producing the same | |
| JPH0215233A (en) | Highly hydrous lens material for eye | |
| DE102013221209A1 (en) | Silicone hydrogel, process for its preparation, molded part thereof and uses | |
| RU2150956C1 (en) | Method of biocompatible material producing | |
| CA1186430A (en) | Modified synthetic hydrogels | |
| WO2022118697A1 (en) | Modifier for ophthalmological device | |
| EP0830412A1 (en) | Biocompatible optically transparent polymeric material based upon collagen and method of making | |
| HK1036421A (en) | Methods of producing intraocular lenses and materials suitable for their production | |
| AU6140500A (en) | Hydrophilic biomedical compositions |